New Research Reveals 7 Conditions Weight Loss Meds Might Treat in Future

By 
Dr Amit Kumar Singh
 on 
Aug 22, 2025
 • 
5
 min read

What if a weight loss medication could transform more than just your body? The rise of new-generation weight loss medications like Wegovy and Mounjaro has been nothing short of revolutionary. Initially celebrated for their powerful effects on type 2 diabetes and obesity, these drugs, known as GLP-1 receptor agonists, are now at the centre of exciting new research. Scientists are discovering that their benefits may extend far beyond the scale, offering new treatments for some of the most challenging health conditions we face today. This isn't just about managing weight; it's about reshaping our approach to overall health. From protecting the heart to preserving brain function, here are seven conditions that these groundbreaking medications might one day treat.

1. Cardiovascular Disease

The link between obesity and cardiovascular disease is well-established, so it's no surprise that weight loss would improve heart health. However, recent studies suggest these drugs do more. The landmark SELECT trial showed that semaglutide (the active ingredient in Ozempic and Wegovy) significantly reduced the risk of heart attack, stroke, or cardiovascular death in patients with pre-existing heart disease and obesity, but without diabetes. Similarly, tirzepatide (Mounjaro and Zepbound) has shown potent cardiovascular benefits, positioning these medications as a new frontier in heart disease prevention.

2. Heart Failure

Heart failure, a condition where the heart struggles to pump blood effectively, could also be a new target for these drugs. The SUMMIT trial provided compelling evidence that tirzepatide could significantly reduce deaths and hospitalisations in patients with a specific type of heart failure known as ‘heart failure with preserved ejection fraction (HFpEF)’, a condition notoriously challenging to treat. Beyond weight reduction, semaglutide has also shown promise in improving heart failure symptoms and physical limitations, according to both global and UK-led studies, suggesting a direct positive effect on heart muscle function.

3. Chronic Kidney Disease

Diabetes is a leading cause of chronic kidney disease (CKD), and protecting kidney function is a critical part of patient care. Research is showing that GLP-1 medications may offer robust protection. Clinical trials are investigating semaglutide as a potential treatment for kidney failure. Studies have also indicated that drugs like tirzepatide can slow the progression of kidney disease in people with type 2 diabetes, offering hope for preserving this vital organ's function long-term.

4. Liver Disease

Metabolically-dysfunction-associated steatotic liver disease, formerly known as non-alcoholic fatty liver disease (NAFLD), is a condition where excess fat builds up in the liver. In its more severe form, metabolic dysfunction-associated steatohepatitis (MASH) can lead to cirrhosis and liver failure. Because these conditions are closely linked to obesity and metabolic health, researchers are optimistic. Clinical trials are currently underway to determine if semaglutide can effectively treat MASH, potentially reversing liver damage and preventing its progression.

5. Neurological Disorders (Alzheimer's & Parkinson's)

Perhaps the most surprising area of research is the potential role of GLP-1 drugs in treating neurodegenerative diseases. Scientists believe these medications may reduce the chronic inflammation in the brain that is associated with conditions like Alzheimer's disease and Parkinson's disease. Early evidence is promising enough that major clinical trials are now underway to see if semaglutide could become a tool to slow or even prevent the progression of these devastating diseases.

6. Addiction and Substance Use Disorders

Anecdotal reports from patients about reduced cravings for alcohol and nicotine have sparked scientific interest in whether GLP-1 drugs could treat addiction. The theory is that these medications may act on the brain's reward pathways, dampening the pleasurable response associated with addictive substances and behaviours. While research is still in its early stages, studies are exploring whether these drugs can help people with substance use disorders by reducing cravings and supporting recovery efforts.

7. Mental Health Conditions

The connection between physical and mental health is undeniable. Beyond the psychological benefits that often accompany significant weight loss, there is emerging evidence that GLP-1 drugs may have a more direct impact on mental well-being. Many users report a quieting of “food noise”, the constant, intrusive thoughts about food, which can significantly reduce anxiety and improve quality of life. Researchers are now exploring if these medications could also have beneficial effects on conditions like depression, potentially by influencing brain chemistry and reducing inflammation.

Conclusion

The landscape of medicine is on the cusp of a significant shift. What started as a new approach to diabetes and obesity is rapidly evolving into a potential multipronged attack on a host of chronic diseases. While much of this research is ongoing and requires further study, the initial findings offer immense hope. As always, it is crucial to speak with a healthcare provider to understand the risks and benefits of any medication. But for the first time, a single class of drugs holds the promise of simultaneously tackling many of modern society's most pressing health challenges.

Could GLP-1 medications be proper for you? At SHEMED, our experts stay on the cutting edge of medical research. Book your consultation now.

References

  1. British Heart Foundation. (n.d.). Wegovy. Retrieved August 7, 2025, from https://www.bhf.org.uk/informationsupport/heart-matters-magazine/medical/ask-the-experts/wegovy
  2. Shemed. (n.d.). What are GLP-1 receptor agonists, and how do they work? Retrieved August 7, 2025, from https://www.shemed.co.uk/blog/what-are-glp-1-receptor-agonists-and-how-do-they-work
  3. Centres for Disease Control and Prevention. (2024, May 15). Heart disease. https://www.cdc.gov/heartdisease/index.htm
  4. UK HFpEF. (n.d.). Home. Retrieved August 7, 2025, from https://www.ukhfpef.org/
  5. National Institute for Health and Care Excellence. (n.d.). Semaglutide for treating metabolic-dysfunction associated steatohepatitis with liver fibrosis [ID6169]. Retrieved August 7, 2025, from https://www.nice.org.uk/guidance/indevelopment/gid-ta11477

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.